Francis Eickman
Cardiovascular Disease · Spartanburg, SCNPI 1578503652
Payments from drug & device makers
Across 121 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$309
- Atricure, Inc.$278
- Johnson & Johnson$265
- AstraZeneca$253
- Novartis$209
- Boston Scientific$142
- plus $638 from 11 others
What the payments were for
- Food & beverage$2,02597%
- Education$221%
- Entertainment$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $309 |
| Atricure, Inc. | 13 | $278 |
| Johnson & Johnson | 16 | $265 |
| AstraZeneca | 11 | $253 |
| Novartis | 13 | $209 |
| Boston Scientific | 2 | $142 |
| Cardiva Medical, Inc. | 7 | $125 |
| E.r. Squibb & Sons, L.L.C. | 7 | $123 |
| Pfizer | 7 | $94 |
| Merck | 4 | $81 |
| Chiesi USA, Inc. | 3 | $52 |
| Hitachi Healthcare Americas Corp. | 1 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Bayer | 2 | $31 |
| Gilead | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,094 in reported general payments places this provider in the 30th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $25,276 |
| Losartan Potassium | 19 | $398 |
| Metoprolol Succinate | 19 | $236 |
| Metoprolol Tartrate | 22 | $155 |
| ClopidogrelClopidogrel Bisulfate | 13 | $150 |
| Atorvastatin Calcium | 16 | $103 |
| Carvedilol | 13 | $50 |
| Furosemide | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $25,27620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Spartanburg
- David RodakSpartanburg$149K
- Nalin SrivastavaSpartanburg$45K
- Ronald LittlefieldSpartanburg$24K
- Alejandro LopezSpartanburg$12K
- Brent McLaurinAnderson$1.1M
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.